Lung cancer
Liquid biopsy guided addition of chemotherapy with TKI in advancedEGFR mutated NSCLC.
Who can joinAdults
Age18–70 years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine and a device and a test
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHINew Delhi, DelhiDirections ↗
Registry summary (technical)
Liquid biopsy guided addition of chemotherapy with TKI in advancedEGFR mutated NSCLC: An open-label, multicentric, phase 3 randomizedcontrolled trial (LiquiACT) - LiquiACT
Sponsor: Indian Council of Medical Research
CTRI/2025/01/079687 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 14 Sep 2026 · read by us 5 Nov 2026